Show simple item record

dc.contributor.authorPérez Manzano, Gerardo
dc.contributor.authorRestrepo Pulgarín, Juan Carlos
dc.date2016-07-04
dc.identifierhttps://revistas.unilibre.edu.co/index.php/biociencias/article/view/2540
dc.identifier10.18041/2390-0512/bioc..2.2540
dc.descriptionBackground: Endometrial cancer (EC) according to statistics is the most common in developed countries where its incidence has been increasing gynecologic tumor. Historically, the EC has been classified into two main types clinicopathological and molecular: type I (endometrioid), representing 80-90% of cases, type II (non-endometrioid subtypes such as: serous cells, clear and undifferentiated carcinomas). An important fact, most patients are diagnosed when the disease is at an early stage, ie when the lesion is still confined to the uterus. Conventional treatment lies in a bilateral salpingo-oophorectomy more primary hysterectomy, either through an abdominal laparotomy or using minimally invasive methods such as laparoscopy or robot-assisted laparoscopy. Objective: To update the knowledge on diagnosis and treatment of endometrial cancer in relation to the various controversies. Methods: Literature was reviewed in English in the last 5 years through 2016. Using key terms: endometrial, cancer, diagnosis and treatment, information was accessed through a search strategy in the database MEDLINE, EMBASE, PubMed, ClinicalKey, Ovid and Cochrane library. Results: It exists in the literature numerous scientific evidence that support from the perspective of endometrial cancer, involving multiple factors over which the diagnosis and treatment of patients defined. Conclusion: Obesity is considered a major risk factor for CE. Treatment should be based on sound medical history, symptoms, age. Consider conservative management in premenopausal patients with genesico desire.en-US
dc.descriptionAntecedentes: El cáncer endometrial (CE) según las estadísticas es el tumor ginecológico más frecuente en países desarrollados, donde su incidencia ha ido en aumento. Históricamente, el CE se ha clasificado en dos tipos principales clínico-patológicos y moleculares: el tipo I (endometrioide), representando el 80-90% de los casos, el tipo II (subtipos no endometrioides tales como: el de células serosas, claras y carcinomas indiferenciados). Como dato importante, la mayoría de las pacientes son diagnosticadas cuando la enfermedad se encuentra en etapas tempranas, es decir cuando la lesión todavía está confinada al útero. El tratamiento convencional radica en una histerectomía primaria más salpingooforectomía bilateral, ya sea por medio de una laparotomía abdominal o utilizando métodos mínimamente invasivos como la laparoscopia o la laparoscopia asistida por robot. Objetivo: Actualizar los conocimientos sobre el Diagnóstico y tratamiento del cáncer endometrial, en relación a las diferentes controversias. Metodología: Se revisó la literatura disponible en inglés en los últimos 5 años hasta el 2016. Utilizando los términos clave: endometrial, cancer, diagnosis y treatment, se accedió a la información mediante una estrategia de búsqueda en la base de datos de MEDLINE, EMBASE, PubMed, ClinicalKey, Ovid y la librería de Cochrane. Resultados: Existe en la literatura numerosas evidencias científicas que fundamentan desde la perspectiva del cáncer endometrial, la participación de múltiples factores sobre los cuales se define el diagnóstico y tratamiento de las pacientes.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Librees-ES
dc.relationhttps://revistas.unilibre.edu.co/index.php/biociencias/article/view/2540/1968
dc.relation/*ref*/International Agency for Research on Cancer/World Health Organization. [Online]. Francia: IARC; 2012 [cited 5 enero 2016]. Globocan “estimated cancer incidence, mortality and prevalence worldwide in 2012”. Disponible en: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx
dc.relation/*ref*/Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011; Primera edición. Bogotá D.C. Instituto Nacional de Cancerología. 2015; 1:148. Report No.: ISBN 978-958-58832-5-3. Disponible en: http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf
dc.relation/*ref*/Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. [Online]. 2010 [5 enero 2016]; 21(11):1851-6. Dispo-nible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962676/
dc.relation/*ref*/Ries LAG, Krapcho M, Mariotto A. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. 2012. Disponible en: http://seer.cancer.gov/archive/csr/1975_2004/
dc.relation/*ref*/Seebacher V, Schmid M, Polterauer S, Hefler-Frischmuth K, Leipold H, Concin N, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer [Internet]. 2009 [7 abril 2016]. Disponible en: http://bmccancer.biomedcentral.com/arti-cles/10.1186/1471-2407-9-460
dc.relation/*ref*/Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet [Internet]. 2000 [6 abril 2016]; 70(2):209-62. Disponible en: http://www.ginecologia.unipd.it/Assistenza-Documenti/Unita’%20operative/Ginecologia%20Onco-logica/staging_booklet.pdf
dc.relation/*ref*/Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer [Internet]. 2006 [6 abril 2016]; 106(4): 804-11. Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/cncr.21649/pdf
dc.relation/*ref*/Morice PH, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet [Internet]. 2015 [citado 15 diciembre 2015]; 387(10023):1094-1108. Disponible en: https://www.clinicalkey.es.ezproxy.uni-librebaq.edu.co/#!/content/journal/1-s2.0-S0140673615001300
dc.relation/*ref*/Aune D, Navarro Rosenblatt DA, Chan DSM, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Annals of Oncology [Internet]. 2015 [citado 10 mayo 2016]; 26(8):1635-48. Disponible en: http://annonc.oxfordjournals.org/content/26/8/1635.long
dc.relation/*ref*/Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. European Journal of Cancer [Internet]. 2015 [citado 10 mayo 2016]; 51(18):2747-58. Disponible en: https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S0959804915008515
dc.relation/*ref*/Brasky ThM, Rodabough RJ, Liu J, Kurta ML, Wise LA, Orchard TS, et al. Long-chain ω-3 fatty acid intake and endometrial cancer risk in the Women’s Health Initiative. Am J Clin Nutr [Internet]. 2015 [citado 11 mayo 2016]; 101(4):824-34. Disponible en: http://ajcn.nutrition.org/content/101/4/824
dc.relation/*ref*/Yang TK, Jung Ch, Chung ChD, Muo ChH, Chang ChH, Huang ChY. Risk of Endometrial Cancer in Women With Pelvic Inflammatory Disease. Medicine [Internet]. 2015 [citado 10 mayo 2016]; 94(34):1278. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602931/
dc.relation/*ref*/Verdoodt F, Friis S, Dehlendorff Ch, Al-bieri V, Kjaer SK. Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: A systematic review and meta-analysis of observational studies. Gynecologic Oncology [Internet]. 2016 [citado 10 mayo 2016]; 140(2):352-8. Disponible en: https://www.clinicalkey.es.ezproxy.uni-librebaq.edu.co/#!/content/journal/1-s2.0-S0090825815302134
dc.relation/*ref*/Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy Ch, et al. Anastrozole ver-sus tamoxifen for the prevention of loco-regional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS). THE LANCET [Internet]. 2016 [citado 9 mayo 2016]; 387(10021):866-73. Disponible en:https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S0140673615011290
dc.relation/*ref*/Rydén L, Arnlind MH, Vitols S, Höistad M, Ahlgren J. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo. THE BREAST [Internet]. 2016 [citado 10 mayo 2016]; 26(1):106-14. Disponible en: https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S0960977616000114
dc.relation/*ref*/Sorosky JI. Endometrial Cancer. Obstetrics & Gynecology [Internet]. 2012 [citado 12 mayo 2016]; 120(2):383-97. Disponible en: http://DOI: 10.1097 / AOG.0b013e3182605bf1
dc.relation/*ref*/Khati NJ, Glanc P, Bhosale PR, Harisinghani MG, Harris RD, Kim YB, et al. ACR Appropriateness Criteria® abnormal vaginal bleeding. AHRQ [Internet]. 2014 [citado 12 mayo; 2016]. p. 13. Disponible en: http://www.gui-deline.gov/content.aspx?id=48294
dc.relation/*ref*/Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women. PRACT ICE BULLETIN. Obstetrics & Gynecology [Internet]. 2012 [citado 12 mayo 2016]; 120(1):197-206. Disponible en: http://www.uptodate.com.ezproxy.unilibrebaq.edu.co:8084/contents/endometrial-carcinoma-clinical-features-and-diagnosis/abstract/12?utdPopup=true
dc.relation/*ref*/Committee Opinion No. 557: Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women. Obstetrics & Gynecology. [Internet]. 2013 [citado 12 mayo 2016]; 121(4):891-6. Disponible en: http:/ /DOI: 10.1097 / 01.AOG.0000428646.67925.9a
dc.relation/*ref*/Su H, Huang L, Huang KG, Feng ChY, Han ChM, Lee ChL. Accuracy of hysteroscopic biopsy, compared to dilation and curettage, as a predictor of final pathology in patients with endometrial cancer. Taiwanese Journal of Obstetrics and Gynecology [Internet]. 2015 [citado 12 mayo 2016]; 54(6):757-60. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S1028455915002454
dc.relation/*ref*/Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic Oncology [Internet]. 2015 [citado 12 mayo 2016]; 137(1):14-22.Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825815006046
dc.relation/*ref*/Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial Thickness Measurement for Detecting Endometrial Cancer in Women With Postmenopausal Bleeding: A Systematic Review and Meta-Analysis. Obstetrics & Gynecology [Internet]. 2010 [citado 13 mayo 2016]; 116(1):160-7: Disponible en: http://DOI: 10.1097 / AOG.0b013e3181e3e7e8
dc.relation/*ref*/Wolfman W, Leyland N, Wolfman W, Heywood M, Singh SS. Asymptomatic Endometrial Thickening. JOGC [Internet]. 2010 [cita-do 13 mayo 2016]; 32(10):990-9. Disponible en: http://www.sciencedirect.com/science/article/pii/S1701216316346904#
dc.relation/*ref*/Menzies R, Wallace S, Ennis M, Bennett A, Jacobson M, Yip G, et al. Significance of Abnormal Sonographic Findings in Postmenopausal Women With and Without Bleeding. JOGC [Internet]. 2011 [citado 13 mayo 2016]; 33(9):944-51. Disponible en: http://www.sciencedirect.com/science/article/pii/S1701216316350204
dc.relation/*ref*/Louie M, Canavan TP, Mansuria S. Threshold for endometrial sampling among postmenopausal patients without vaginal bleeding. International Journal of Gynecology & Obstetrics [Internet]. 2016 [citado 13 mayo 2016]; 132(3):314-7. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S002072921500661X
dc.relation/*ref*/Kondalsamy-Chennakesavan S, Yu Ch, Kattan MW, Yee L, Sykes P, Nascimento M, et al. Nomograms to predict isolated loco-regional or distant recurrence among women with uterine cancer. Gynecologic Oncology [Internet]. 2012 [citado 15 mayo 2016]; 125(3):520-5. Disponible en: http://dx.doi.org/10.1016/j.ygyno.2012.02.022
dc.relation/*ref*/Ayeni TA, Bakkum-Gamez JN, Mariani A, McGree ME, Weaver AL, Eglefino MG, et al. Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. Gynecologic Oncology [Internet]. 2013 [citado 15 mayo 2016]; 129(3):478-85. Disponible en: http://dx.doi.org/10.1016/j.ygyno.2013.03.011
dc.relation/*ref*/Aristizabal P, Graesslin O, Barranger E, Clavel-Chapelon F, Haddad B, Luton D, et al. A suggested modification to FIGO stage I endometrial cancer. Gynecologic Oncology [Internet]. 2014 [citado 13 mayo 2016]; 133(2):192-6. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825814002418
dc.relation/*ref*/Torralba AE, González E, Callejo J, Lailla JL. Utilidad de la resonancia magnética en la estadificación prequirúrgica del cáncer de endometrio. Clínica e Investigación en Ginecología y Obstetricia [Internet]. 2014 [citado 19 mayo 2016]; 41(3):104-6. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S0210573X13000282
dc.relation/*ref*/Husby JA, Salvesen DO, Magnussen IJ, Tro-vik J, Björge L, Salvesen HB, et al. Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology [Internet]. 2015 [citado 15 mayo 2016]; 70(5):487-94. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0009926015000203?scrollTo=%23bib45051
dc.relation/*ref*/Creasman WT, Scott D. Adenocarcinoma of the Uterine Corpus. In Di Saia PhJ, Creasman WT. Clinical Gynecologic Oncology. 8a ed. Philadelphia: Elsevier, Inc; 2012. p. 141-174.
dc.relation/*ref*/Tuomi T, Pasanen A, Luomaranta A, Le-minen A, Bützow R, Loukovaara M. Risk-stratification of endometrial carcinomas revisited: A combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease. Gynecologic Oncology [Internet]. 2015 [citado 19 mayo 2016]; 137(1):23-7. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S0090825815005880
dc.relation/*ref*/Burgmann E, Yun-Yi H, Armstrong A. The Value of Additional Pathology Comments Indicating Suspicion of Adenocarcinoma Among Women Diagnosed Preoperatively With Complex Atypical Endometrial Hyperplasia. Gynecological Pathology [Internet]. 2012 [citado 18 mayo 2016]; 31(3):222-6. Disponible en: http://DOI: 10.1097 / PGP.0b013e31823ef8b0
dc.relation/*ref*/Zhou L, Meng Zh, Wu Y, Zhu H, Wang X. Prediction of endometrial carcinogenesis probability while diagnosed as atypical endometrial hyperplasia: a new risk model based on age, CA199 and CA125 assay. European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2014 [citado 18 mayo 2016]; 183(1):5-9. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S0301211514005302
dc.relation/*ref*/Ellenson LH, Pirog EC. The Female Genital Tract. In Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 9a ed. Philadelphia: Elsevier Inc. 2015. p. 991-1042.
dc.relation/*ref*/Siegel R, Ma J, Zou Z, Jemal A. Cancer statis-tics, 2014. CA: A Cancer Journal for Clinicians [Internet]. 2014 [citado 14 diciembre 2015]; 64(1):9-29. Disponible en: http://onlineli-brary.wiley.com/doi/10.3322/caac.21208/full
dc.relation/*ref*/Burke WM, Gold MA. Practice Bulletin Endometrial Cancer. Obstetrics & Gynecology [Internet]. 2015 [citado 2 marzo 2016]; 125(4):1006-26. Disponible en: http://ovidsp.tx.ovid.com.ezproxy.unilibrebaq.edu.co:8084/sp-3.19.0a/ovidweb.cgi?&S=FHICFPKINODDNOFHNCIKLFOBCABPAA00&Browse=Toc+Children%7cYES%7cS.sh.3561_1460827607_44.3561_1460827607_56.3561_1460827607_65.3561_1460827607_66.356
dc.relation/*ref*/Lu KH, Loose DS, Yates MS, Nogueras GM, Munsell MF, Chen LM, Lynch H, et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev Res (Phila) [Internet]. 2013 [citado 11 mayo 2016]; 6(8):774-81. Disponible en: http://cancerpreventionresearch.aacrjournals.org/content/6/8/774.full.pdf+html
dc.relation/*ref*/Morelli M, Di Cello A, Venturella R, Mocciaro R, D’Alessandro P, Zullo F. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women. Gynecol. Endocrinol.[Internet]. 2013; 29(2):156-9. Disponible en: https://www.researchgate.net/profile/Annalisa_Di_Cello/publication/233327951_Efficacy_of_the_levonorgestrel_intrauteri-ne_system_(LNG-IUS)_in_the_prevention_of_the_atypical_endometrial_hyperplasia_and_endometrial_cancer_retrospectiv
dc.relation/*ref*/Linkov F, Elishaev E, Gloyeske N, Edwards R, Althouse A, Geller M, et al. Bariatric surgery-induced weight loss changes immune markers in the endometrium of morbidly obese women. Surgery for Obesity and Related Diseases [Internet]. 2014; 10(5):921-6. Dispo-nible en: https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S1550728914001464
dc.relation/*ref*/Nasir M, Khan G, Ariffin R, Abu J, Chapman C, Deen S, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help? Ecologic Oncology. [Internet]. 2014; 132(1):248-53. Disponible en: https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S0090825813012778
dc.relation/*ref*/Gressel G, Parkash V y Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. International Journal of Gynecology & Obstetrics [Internet]. 2015 [citado 11 mayo 2016]; 131(3):234-9. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S002072921500572X
dc.relation/*ref*/Lécuru F, Bats A, Ngô C, Bensaid C, Achou-ri A, Makke L, et al. Linfadenectomías en el cáncer de endometrio. Ginecología-Obstetricia [Internet]. 2015 [citado 11 mayo 2016]; 51(4):1-6. Disponible en: https://www.cli-nicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/emc/51-s2.0-S1283081X15747429?scrollTo=%23hl0000357
dc.relation/*ref*/Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol [Internet]. 1995 [8 abril 2016]; 56(1):29-33.Dis-ponible en: http://www.sciencedirect.com/science/article/pii/S0090825885710050
dc.relation/*ref*/Chan JK, Cheung MK, Huh WK, Osann K, Hu-sain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer [Internet]. 2006 [8 abril 2016]; 107(8):1823-30. Disponible en: http://cat.inist.fr/?aModele=afficheN&cpsidt=18197112
dc.relation/*ref*/Cuadra M, Ceberio N, Rodríguez M, Mendizabal J, Gorostiaga J y Lete I. Tratamiento quirúrgico del cáncer de endometrio: ¿qué pasa-ría si no realizamos biopsia intraoperatoria? Progresos de obstetricia y ginecología [Internet]. 2015; 58(10):446-51. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0304501315001557?scrollTo=%23bib0200
dc.relation/*ref*/Kyung HH, Noh HP, Hee SK, Hyun HC, Jae WK y Yong SS. Peritoneal cytology: A risk factor of recurrence for non-endometrioid endometrial cancer. Gynecologic Oncology [Internet]. 2014 [citado 11 mayo 2016]; 134(2):293-6. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825814009652?scrollTo=%23hl0000604
dc.relation/*ref*/Scalici J, Laughlin B, Finan M, Wang B y Rocconi R. The trend towards minimally invasive surgery (MIS) for endometrial cancer: An ACS-NSQIP evaluation of surgical outcomes. Gynecologic Oncology [Internet]. 2015 [citado 11 mayo 2016]; 136(3):512-5. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825814014796
dc.relation/*ref*/Chan J, Gardner A, Taylor K, Thompson C, Blansit K, Yu X, et al. Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - A comparative analysis of total charges and complication rates. Gynecologic Oncology. [Internet]. 2015 [citado 11 mayo 2016]; 139(2):300-5. Disponible en: https://www-clinicalkey-es.consul-taremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825815301232
dc.relation/*ref*/Corrado G, Chiantera V, Fanfani F, Cutillo G, Lucidi A, Mancini E, et al. Robotic Hysterectomy in Severely Obese Patients With Endometrial Cancer: A Multicenter Stud. Journal of Minimally Invasive Gynecology [Internet]. 2016 [citado 11 mayo 2016].; 23(1):94-100. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S1553465015015101
dc.relation/*ref*/Favero G, Miglino G, Köhler Ch, Pfiffer T, Silva e Silva A, Ribeiro A, et al. Herramientas para compartir y guardar. Journal of Minimally Invasive Gynecology [Internet]. 2015 [citado 11 mayo 2016]; 22(6):938-43. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S1553465015003258
dc.relation/*ref*/Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol [Internet]. 2004 [21 abril 2016]; 92:744-51. Disponible en: http://ovidsp.tx.ovid.com.ez-proxy.unilibrebaq.edu.co:8084/sp-3.19.0a/ovidweb.cgi?WebLinkFrameset=1&S=FGJCFPKAKGDDHOMANCIKJGJCGNNHAA00&returnUrl=ovidweb.cgi%3f%26Titles%3dS.sh.22%257c1%257c10%26FORMAT%3dtitle%26FIELDS%3dTITLES%26S%3
dc.relation/*ref*/Homesley H, Filiaci V, Gibbons S, Long H, Ce-lla D, Spirtos N, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic On. Gynecologic Oncology [Internet]. 2009 [citado 16 mayo 2016]; 112(3):543-52. Disponible en: https://www.clinicalkey.es.ezproxy.uni-librebaq.edu.co/#!/content/journal/1-s2.0-S0090825808009384
dc.relation/*ref*/Nout R, Van de Poll-Franse L, Lybeert M, Wárlám-Rodenhuis C, Jobsen J, Mens J, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in. endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol [Internet]. 2011 [citado 16 mayo 2016]; 29(13):1692-1700. Disponible en: https://pure.uvt.nl/portal/files/1379512/MedPst_Poll-franse_longterm__JCO_2011.pdf
dc.relation/*ref*/Ly D, Soisson P, Dodson M, Sause W y Gaffney D. Adjuvant radiation therapy is associated with improved pelvic control and overall survival in FIGO IB endometrial carcinoma with high grade histology. Gynecologic Oncology [Internet]. 2015 [citado 16 mayo 2016]; 138(3):526-31. Disponible en: https://www-clinicalkey-es.consultaremo-ta.upb.edu.co/#!/content/journal/1-s2.0-S0090825815300433
dc.relation/*ref*/Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol [Internet]. 2004 [21 abril 2016]; 22(11):2159-66. disponible en: http://www.kalbemed.com/Portals/6/komelib/oncology/Onkologi/Filgrastim/fil-grastim%20ca%20endometrium.pdf
dc.relation/*ref*/Colombo N, Creutzberg C, Amant F, Bos-se T, González-Martín A, Ledermann J, et al. ESMO–ESGO–ESTRO consensus confe-rence on endometrial cancer: Diagnosis, treatment and follow-up. Radiotherapy and Oncology [Internet]. 2015 [citado 16 abril 2016]; 117(3):559-81. Disponible en: https://www.clinicalkey.es.ezproxy.unilibrebaq.edu.co/#!/content/journal/1-s2.0-S0167814015006180
dc.relation/*ref*/Sun Ch, Chen G, Yang Z, Jiang J, Yang X, Li N, et al. Safety of ovarian preservation in young patients with early stage endometrial cancer: a retrospective study and meta-analysis. Fertility and Sterility [Internet]. 2013 [citado 11 mayo 2016]; 100(3):782-7. Disponible en: https://www.clinicalkey.es.ezproxy.uni-librebaq.edu.co/#!/content/journal/1-s2.0-S0015028213006420
dc.relation/*ref*/Boggess JF, Kilgore JE. Uterine Cancer. In Niederhuber JE, Armitage JO, Doroshow JH, et al editores. Abeloff’s Clinical Oncology. 5a ed. Philadelphia: Elsevier, Inc; 2014. p. 1575-91.
dc.relation/*ref*/Simpson A, Feigenberg T, Clarke B, Gien L, Ismiil N, Laframboise S, et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecologic Oncology [Internet]. 2014 [citado 11 mayo 2016]; 133(2):229-33. Disponible en: https://www-clinicalkey-es.consultaremota.upb.edu.co/#!/content/journal/1-s2.0-S0090825814001383
dc.rightsDerechos de autor 2018 Biocienciases-ES
dc.rightshttps://creativecommons.org/licenses/by-sa/4.0/es-ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.sourceBiociencias; Vol 11 No 2 (2016): Biociencias; 39-53en-US
dc.sourceBiociencias; Vol. 11 Núm. 2 (2016): Biociencias; 39-53es-ES
dc.source2390-0512
dc.source0124-0110
dc.titleDISPUTES REGARDING THE DIAGNOSIS AND TREATMENT OF CANCER ENDOMETRIAL. AN UPDATEen-US
dc.titleCONTROVERSIAS EN RELACIÓN AL DIAGNÓSTICO Y TRATAMIENTO DEL CÁNCER ENDOMETRIAL. UNA ACTUALIZACIÓN.es-ES
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.type.coarhttp://purl.org/coar/resource_type/c_6501
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
dc.relation.ispartofjournalRevistas - Ciencias de la Saludspa
dc.subject.proposalCáncerendometriales-ES
dc.subject.proposalFactor de riesgoes-ES
dc.subject.proposalObesidades-ES


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Derechos de autor 2018 Biociencias
Except where otherwise noted, this item's license is described as Derechos de autor 2018 Biociencias